BRIEF—EMA to up capacity for COVID-19 vaccine from AstraZeneca


The European Medicines Agency’s human medicines committee (CHMP) has approved a new site to manufacture Vaxzevria (previously COVID-19 Vaccine AstraZeneca) finished product.

The site, operated by WuXi Biologics, is located in Leverkusen, Germany.

In addition to this new manufacturing facility, the CHMP has also given a positive opinion to scale up manufacturing to triple the batch size of finished product at a site operated by Amylin Ohio in West Chester Township, Ohio, the USA.

These changes are expected to support the continued supply of Vaxzevria in the European Union and donations to third countries through the COVID-19 Vaccines Global Access (COVAX) initiative.

AmylinAstraZenecaBiotechnologyCoronavirusEuropeEuropean Medicines AgencyFocus OnGermanyInfectious diseasesProduction监管UKUSAVaccinesVaxzevriaWuXi Biologics

AstraZeneca, COVID-19, Vaxzevria, Production, EMA, CHMP, Approval, Wuxi Biologics, Amylin, COVAX

Your Comments

Loginto add a comment

There are no comments yet. Be the first and leave a response!

Back to top